Percutaneous revascularization of chronic coronary occlusions: an overview.

Patients with a chronic coronary occlusion often undergo coronary angiography after weeks to months of occlusion. The published reports underestimate the extent of this problem because such patients are often arbitrarily assigned to receive medical therapy or undergo bypass surgery as a result of poor success with percutaneous revascularization and substantial restenosis. Thus, there is controversy about the role of angioplasty in this patient cohort. The goal of this overview was to evaluate the available information about angioplasty in chronic coronary occlusions. The primary indication for attempted recanalization of a chronic coronary occlusion has been symptomatic angina pectoris. Anginal status often improves after successful procedures (70% vs. 31% with a failed procedure); left ventricular function may improve; and subsequent referral for coronary artery bypass graft surgery is uncommon (3% vs. 28% in unsuccessful cases). Successful recanalization is achieved in approximately 65% of attempted procedures. Inability to cross the stenosis with a guide wire is the most common cause of procedural failure. Statistically significant predictors of procedural success include older occlusions (75% < 3 months old vs. 37% > or = 3 months old), absence of any anterograde flow through the occlusion (76% with vs. 58% without), angiographically abrupt-appearing occlusions (50% vs. 77% with tapered occlusions), presence of bridging collateral vessels (23% with vs. 71% without) and lesions > 15 mm. Procedural complications occur at a slightly lower incidence than in angioplasty of high grade subtotal stenoses. Long-term success is limited, and restenosis can be expected in > 50% of the patients. The experience with chronic total occlusions of saphenous vein bypass grafts is small, but there appear to be limited procedural success and significant procedural complications, particularly associated with distal emboli. The role of new pharmacologic agents has yet to be defined and that of new devices has been disappointing so far, but further technologic advances are on the horizon.

[1]  H. Trappe,et al.  Natural history of single vessel disease. Risk of sudden coronary death in relation to coronary anatomy and arrhythmia profile. , 1989, European heart journal.

[2]  A. Jacobs,et al.  Results of coronary angioplasty of chronic total occlusions (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Angioplasty Registry). , 1992, The American journal of cardiology.

[3]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[4]  J. Margolis,et al.  Diffuse Embolization Following Percutaneous Transluminal Coronary Angioplasty of Occluded Vein Grafts: The Blush Phenomenon , 1991, Clinical cardiology.

[5]  L. Hillis,et al.  Influence of residual antegrade coronary blood flow on survival after myocardial infarction in patients with multivessel coronary artery disease , 1990 .

[6]  G. Vetrovec,et al.  Early and late outcome of percutaneous transluminal coronary angioplasty for subacute and chronic total coronary occlusion. , 1986, American heart journal.

[7]  A. Colombo,et al.  Coronary angioplasty of chronic occlusions: factors predictive of procedural success. , 1992, American heart journal.

[8]  Foss Mv HOMOSEXUAL PRACTICE AND VENEREAL DISEASES. , 1964, Lancet.

[9]  D. Kereiakes,et al.  Angioplasty in total coronary artery occlusion: experience in 76 consecutive patients. , 1985, Journal of the American College of Cardiology.

[10]  L. Hillis,et al.  Does restoration of antegrade flow in the infarct‐related coronary artery days to weeks after myocardial infarction improve long‐term survival? , 1992 .

[11]  W Rutishauser,et al.  Percutaneous transluminal coronary angioplasty for chronic total coronary arterial occlusion. , 1987, The American journal of cardiology.

[12]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[13]  S. Kelsey,et al.  Effect of investigator experience on percutaneous transluminal coronary angioplasty. , 1984, The American journal of cardiology.

[14]  P. Golino,et al.  Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. , 1989, Journal of the American College of Cardiology.

[15]  B. Waller,et al.  Anatomy, histology, and pathology of coronary arteries: A review relevant to new interventional and imaging techniques‐part iv , 1992, Clinical cardiology.

[16]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[17]  H. Rapold Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation , 1990, The Lancet.

[18]  J. Maraganore,et al.  Anticoagulant activity of synthetic hirudin peptides. , 1989, The Journal of biological chemistry.

[19]  W J Penny,et al.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.

[20]  D. Pryor,et al.  The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. , 1994, The New England journal of medicine.

[21]  T. Bowker,et al.  Percutaneous transluminal coronary angioplasty in chronic coronary artery occlusion. , 1993, Journal of the American College of Cardiology.

[22]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[23]  J. Simpson,et al.  Effect of lesion characteristics on outcome of directional coronary atherectomy. , 1991, Journal of the American College of Cardiology.

[24]  B. Meier,et al.  Magnum wire for balloon recanalization of chronic total coronary occlusions. , 1989, The American journal of cardiology.

[25]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[26]  G. Stone,et al.  Procedural outcome of angioplasty for total coronary artery occlusion: an analysis of 971 lesions in 905 patients. , 1990, Journal of the American College of Cardiology.

[27]  V. Bufalino,et al.  Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts by extended infusion of urokinase: initial results and short-term clinical follow-up. , 1991, Journal of the American College of Cardiology.

[28]  C. McCabe,et al.  Initial success and long-term follow-up of percutaneous transluminal coronary angioplasty in chronic total occlusions versus conventional stenoses. , 1988, The American journal of cardiology.

[29]  M. Leon,et al.  Chronic total obstruction and short-term outcome: the Excimer Laser Coronary Angioplasty Registry experience. , 1993, Mayo Clinic proceedings.

[30]  E. Topol,et al.  Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.

[31]  A. Jaffe,et al.  Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.

[32]  P. Serruys,et al.  Percutaneous transluminal angioplasty of a totally occluded venous bypass graft: a challenge that should be resisted. , 1989, The American journal of cardiology.

[33]  V. Fuster,et al.  Role of Thrombin in Arterial Thrombosis: Implications for Therapy , 1991, Thrombosis and Haemostasis.

[34]  E. Topol,et al.  Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion. , 1989, The American journal of cardiology.

[35]  B. Meier Total coronary occlusion: a different animal? , 1991, Journal of the American College of Cardiology.

[36]  W. Weintraub,et al.  Percutaneous Transluminal Coronary Angioplasty of Chronic Total Occlusions: Primary Success, Restenosis, and Long‐term Clinical Follow‐up , 1992, Circulation.

[37]  H. Hecht,et al.  Lesion morphology and coronary angioplasty: current experience and analysis. , 1992, Journal of the American College of Cardiology.

[38]  J. Wilcox Thrombin and other potential mechanisms underlying restenosis. , 1991, Circulation.

[39]  G. Roubin Interventional Cardiovascular Medicine: Principles and Practice , 1994 .

[40]  W. Rutishauser,et al.  Long-term results of successful and failed angioplasty for chronic total coronary arterial occlusion. , 1990, The American journal of cardiology.

[41]  P. Serruys,et al.  Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. , 1993, Circulation.

[42]  N Sulke,et al.  Determinants of success of coronary angioplasty in patients with a chronic total occlusion: a multiple logistic regression model to improve selection of patients. , 1993, British heart journal.

[43]  Burton E. Sobel,et al.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.

[44]  F. Schwarz,et al.  Intraoperative evaluation of the functional significance of coronary collateral vessels in patients with coronary artery disease. , 1978, The American journal of cardiology.

[45]  P. Siegl,et al.  Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide: A Potent Inhibitor of Coagulation Factor Xa in a Primate Model of Arterial Thrombosis , 1991, Circulation.

[46]  H. Schaff,et al.  Angioplasty in total coronary artery occlusion. , 1984, Journal of the American College of Cardiology.

[47]  M. Bell,et al.  Balloon angioplasty of chronic total coronary artery occlusions: what does it cost in radiation exposure, time, and materials? , 1992, Catheterization and cardiovascular diagnosis.

[48]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[49]  K. Kuck,et al.  Recanalization of chronic, totally occluded coronary arteries by new angioplasty systems. , 1990, The American journal of cardiology.

[50]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[51]  R. Jordan,et al.  Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. , 1989, Circulation.

[52]  S. Kaul,et al.  An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. , 1992, The New England journal of medicine.

[53]  A. Jacobs,et al.  Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty. , 1991, The American journal of cardiology.

[54]  D. Hunt,et al.  Coronary angioplasty for chronic total occlusion reduces the need for subsequent coronary bypass surgery. , 1990, American heart journal.

[55]  R. Califf,et al.  From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. , 1989, Journal of the American College of Cardiology.

[56]  M. Cohen,et al.  Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. , 1989, Journal of the American College of Cardiology.

[57]  P. Serruys,et al.  Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. , 1985 .

[58]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[59]  K. Bailey,et al.  Initial and Long‐term Outcome of 354 Patients After Coronary Balloon Angioplasty of Total Coronary Artery Occlusions , 1992, Circulation.

[60]  H. Gold,et al.  Kistrin, a Polypeptide Platelet GPIIb/IIIa Receptor Antagonist, Enhances and Sustains Coronary Arterial Thrombolysis With Recombinant Tissue‐Type Plasminogen Activator in a Canine Preparation , 1991, Circulation.

[61]  J. Griffin,et al.  Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. , 1990, Circulation.

[62]  V. Bufalino,et al.  Prolonged infusion of urokinase for recanalization of chronically occluded aortocoronary bypass grafts. , 1988, The American journal of cardiology.

[63]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[64]  W. Edwards,et al.  Balloon angioplasty of aortocoronary saphenous vein bypass grafts: a histopathologic study of six grafts from five patients, with emphasis on restenosis and embolic complications. , 1988, Journal of the American College of Cardiology.

[65]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .